Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room C-278, New York, NY 10065, USA.
Radiology. 2011 Jan;258(1):41-56. doi: 10.1148/radiol.10092129.
Cancer chemotherapy has evolved from cytotoxic agents and now includes several new agents that target specific molecules responsible for the regulation of cell growth, nutrient supply, and differentiation. These molecularly targeted therapies have a different mechanism of action than do classic cytotoxic agents, which predominantly attack rapidly proliferating cells. Not surprisingly, therefore, the toxicity of targeted and cytotoxic agents may differ in both clinical and radiologic presentation. Many of the toxicities of targeted therapies are not cumulative or dose dependent, some are asymptomatic, and others may first manifest radiologically. It is imperative that radiologists be aware of these toxicities and that they learn to recognize the relevant findings so that they can provide a complete differential diagnosis and thus play an important role in patient care.
癌症化疗已经从细胞毒性药物发展而来,现在包括几种针对负责细胞生长、营养供应和分化调节的特定分子的新型药物。这些分子靶向疗法的作用机制与经典细胞毒性药物不同,后者主要攻击快速增殖的细胞。因此,毫不奇怪,靶向和细胞毒性药物的毒性在临床和影像学表现上可能有所不同。许多靶向治疗的毒性不是累积的或剂量依赖性的,有些是无症状的,而另一些可能首先在影像学上表现出来。放射科医生必须意识到这些毒性,并学会识别相关的发现,以便能够提供完整的鉴别诊断,从而在患者的治疗中发挥重要作用。